V
32.55
0.22 (0.68%)
| Penutupan Terdahulu | 32.33 |
| Buka | 32.33 |
| Jumlah Dagangan | 2,280,793 |
| Purata Dagangan (3B) | 3,000,755 |
| Modal Pasaran | 3,761,292,288 |
| Harga / Buku (P/B) | 6.42 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Apr 2026 |
| EPS Cair (TTM) | -1.54 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.11% |
| Nisbah Semasa (MRQ) | 25.86 |
| Aliran Tunai Operasi (OCF TTM) | -152.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -102.10 M |
| Pulangan Atas Aset (ROA TTM) | -14.99% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.99% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Viking Therapeutics, Inc. | Menurun | Bercampur |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.00 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.15% |
| % Dimiliki oleh Institusi | 70.06% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| AUBUCHON NEIL WILLIAM | 34.66 | - | 4,475 | 155,104 |
| Jumlah Keseluruhan Kuantiti Bersih | 4,475 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 155,104 | |||
| Purata Pembelian Keseluruhan ($) | 34.66 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| AUBUCHON NEIL WILLIAM | Pegawai | 10 Mar 2026 | Beli (+) | 4,475 | 34.66 | 155,104 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 04 Feb 2026 | Pengumuman | Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 |
| 12 Jan 2026 | Pengumuman | Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity |
| 10 Jan 2026 | CNBC | 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market |
| 08 Jan 2026 | Pengumuman | Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity |
| 07 Jan 2026 | Pengumuman | Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer |
| 05 Jan 2026 | Pengumuman | Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |